Login to Your Account

As 2Q Numbers Jump

Amgen Bone-Picks GSK, But No J&J Replay in D-mab Deal

By Randy Osborne

Monday, August 3, 2009
Amgen Inc.'s rise in second-quarter earnings and the overseas deal with GlaxoSmithKline plc for denosumab sent the stock up last week, but left questions about the rest of 2009 as well as the bone-drug pipeline star, especially with regard to osteonecrosis of the jaw - a side effect that has also bedeviled (apparently to a lesser extent) competitor Zometa.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription